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Abstract
Background: The Wake-Up T2MI Registry is a retrospective cohort study investigat-
ing patients with type 2 myocardial infarction (T2MI), acute myocardial injury, and
chronic myocardial injury. We aim to explore risk stratification strategies and investi-
gate clinical characteristics, management, and short- and long-term outcomes in this
high-risk, understudied population.
Methods: From 1 January 2009 to 31 December 2010, 2846 patients were identified
with T2MI or myocardial injury defined as elevated cardiac troponin I with at least
one value above the 99th percentile upper reference limit and coefficient of variation
of 10% (>40 ng/L) and meeting our inclusion criteria. Data of at least two serial tro-
ponin values will be collected from the electronic health records to differentiate
between acute and chronic myocardial injury. The Fourth Universal Definition will be
used to classify patients as having (a) T2MI, (b) acute myocardial injury, or (c) chronic
myocardial injury during the index hospitalization. Long-term mortality data will be
collected through data linkage with the National Death Index and North Carolina
State Vital Statistics.
Results: We have collected data for a total of 2205 patients as of November 2018.
The mean age of the population was 65.6 ± 16.9 years, 48% were men, and 64%
were white. Common comorbidities included hypertension (71%), hyperlipidemia
(35%), and diabetes mellitus (30%). At presentation, 40% were on aspirin, 38% on
β-blockers, and 30% on statins.
Conclusion: Improved characterization and profiling of this cohort may further
efforts to identify evidence-based strategies to improve cardiovascular outcomes
among patients with T2MI and myocardial injury.
ABBREVIATIONS: CAD, coronary artery disease; cTnI, cardiac troponin I; CTSI, Clinical and
Translational Science Institute; CV, cardiovascular; ICD, International Classification of
Disease; REDCap, Research Electronic Data Capture; T1MI, type 1 myocardial infarction;
T2MI, type 2 myocardial infarction; WFUBMC, Wake Forest University Baptist Medical
Center.
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1 | INTRODUCTION
Myocardial necrosis due to myocardial ischemia is designated as myo-
cardial infarction (MI). Recognizing the heterogeneity inherent to this
entity, in 2007 and 2012, the ESC/ACCF/AHA/WHF Task Force for
the Universal Definition of MI released expert consensus documents
redefining MI into five types.1 This classification system was recently
further refined with the Fourth Universal Definition of MI.2 Type
1 myocardial infarction (T1MI) refers to acute coronary syndrome
(ACS) caused by atherosclerotic plaque rupture, ulceration, fissure, or
erosion leading to intraluminal thrombus formation and obstructed
coronary blood flow. Type 2 myocardial infarction (T2MI) was defined
as myocardial ischemia, not due to plaque rupture but secondary to
an imbalance between myocardial oxygen demand and/or supply due
to an underlying cause.2 In defining presence of MI, a critical charac-
teristic is presence of myocardial ischemia; this may be manifested by
symptoms, changes on electrocardiography, or evidence for loss of
myocardial function. Patients with evidence of elevated troponin with
at least one value above the 99th percentile upper reference limit
(URL) and 10% coefficient of variation without overt myocardial
ischemia are classified as having myocardial injury.2 This injury may be
acute or chronic, depending on the pattern of cTn elevation and in
appropriate clinical contexts.
T2MI and myocardial injury are commonly encountered in clinical
practice. In smaller studies, T2MI has been found to be responsible for
2% to 37% of all elevated troponin results in unselected hospitalized
patients and 5% to 71% in an unselected emergency department set-
ting.3–7 Similarly, myocardial injury has been reported in up to 70% of
unselected patients.8,9 The heterogeneity in reported frequencies
across studies is likely due to differences in biomarkers cut-offs,
selected populations, variation in adjudication processes, and chal-
lenges in clinically distinguishing myocardial injury from infarction.
Short- and long-term event rates are higher among patients who
experience T2MI compared with patients with T1MI1,3,4,8,10–28
(Table 1). Although the role of underlying coronary artery disease
(CAD) and microvascular disease remains unclear, it may play an
essential role in influencing outcomes in T2MI.10,29 Rates of obstruc-
tive CAD in T2MI patients undergoing coronary angiography range
from 28% to 78%.3,8,9,27 Despite a high prevalence of CAD in these
patients, significant disparities exist in medical management of even
those with CAD in T2MI or myocardial injury, when compared with
those with T1MI1,3,4,8–12,14,15,19–27 (Table 2).
Relatively few studies are available comprehensively characteriz-
ing the longitudinal profile, medical and interventional management,
and short- and long-term clinical prognosis of patients with T2MI or
myocardial injury.26 There is a lack of consensus on the optimal
therapeutic approach to this heterogeneous cohort of patients, includ-
ing whether they benefit similarly from guideline-based ACS therapies
(as T1MI).30 Although select studies have characterized patients with
T2MI, patients with myocardial injury have been infrequently studied.
Few studies have leveraged linked national and state death records to
facilitate more complete mortality estimates.
Our study has the following objectives: (a) to explore clinical char-
acteristics of patients with T2MI and myocardial injury; (b) to investi-
gate the differences in presentation, stratified by age, sex, and race;
(c) to characterize utilization of noninvasive and invasive ischemic
evaluation strategies in this population; (d) to determine the rates and
burden of obstructive CAD; (e) to determine differences in medical
and interventional management of T2MI and myocardial injury; (f) to
investigate causes of cardiovascular and noncardiovascular mortality
in T2MI and myocardial injury; (g) to identify predictors of in-hospital,
180-days, 1-year, 5-year, and 7-year outcomes.
2 | METHODS
The Wake-Up T2MI Registry is a registry of adults (age ≥ 18 years)
who were hospitalized at Wake Forest University Medical Center in a
2-year period between 1 January 2009 and 31 December 2010, and
had T2MI or myocardial injury as defined by the Fourth Universal
Definition of MI.2 Figure 1 provides an outline of the study design
and patient selection.
2.1 | Data source
The Clinical and Translational Science Institute (CTSI) at Wake Forest
University Baptist Medical Center (WFUBMC), Winston-Salem, North
Carolina, will serve as the data source and primary organization for
this registry. WFUBMC is an academic medical center with
885 licensed beds and is designated as a level I trauma center, serving
24 counties in northwest North Carolina and southwest Virginia. Elec-
tronic health records from CTSI will be accessed to study demo-
graphics, admission diagnosis, discharge diagnosis, laboratory tests,
medications, medical history, procedures, and clinical notes for indi-
viduals meeting the specified criteria. Mortality data have been
obtained from the National Death Index (NDI) and North Carolina
State Vital Statistics from 1 January 2009 to 31 December 2017, and
will be utilized for ascertainment of death as an outcome. The study
protocol has been approved by the regional Internal Review Board at
WFUBMC. This registry is registered in Registry of Patient Registries
(RoPR) with RoPR ID number of 43530.
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TABLE 1 Mortality rate of T2MI and myocardial injury in selected studies
Study N
Mortality of T1MI
patients
Mortality of T2MI
patients
Mortality of
myocardial
injury patients
Mortality of T2MI
vs T1MI patients
Mortality of
myocardial injury
vs T1MI patients
Mortality of T2MI
vs myocardial
injury
Putot et al
(2018)19
4436 (conventional
cTnI ≥10 μg/L)
125 (6.1%) in-
hospital
mortality
133 (14%) in-
hospital
mortality
260 (17.9%) in-
hospital
mortality
Lambrecht et al
(2018)20
1568 (cTnI
>30 ng/L)
114 of 360 (32%)
at 3.2 years.
CVD:
68 (61.3%)
74 of 119 (62%)
at 3.2 years.
CVD:
29 (42.6%)
639 of 1089
(59%) at
3.2 years.
CVD:
252 (41.2%)
NA NA No difference T2MI
vs myocardial
injury
Smilowitz et al
(2018)21
710 (cTnI
>0.06 ng/mL)
41 (29.9%) of
137 at
1.8 years.
18 (13%) in-
hospital death
45 (30.8%) of
146 at
1.8 years.
17 (12%) in-
hospital death
52 (29.7%) of
175 at
1.8 years.
16 (9%) in-
hospital
No difference T2MI
vs myocardial
injury
Arora et al
(2018)22
1039 (NSTEMI) 12.4% of 775 at
1 year
34.9% of 264 at
1 year
2.80 (2.13-3.67) RR
(95% CI)
Chapman et al
(2018)10
2122 (cTnI
≥0.05 μg/L)
430 (37%) at
4.9 years all-
cause. CVD:
253 (22%)
268 (63%) at
4.9 years all-
cause. CVD:
104 (24%)
378 (72%) at
4.9 years all-
Cause. CVD:
145 (28%)
1.51 (1.21-1.87) RR
(95% CI).
Adjusted age,
sex, renal
function, Hb,
smoking,
diabetes, HTN,
CAD, stroke,
PVD. 2.15
(1.82-2.55)
unadjusted
2.09 (1.72-2.55)
RR (95% CI).
Adjusted age,
sex, renal
function, Hb,
smoking,
diabetes, HTN,
CAD, stroke,
PVD. 2.88
(2.43-3.40)
unadjusted
1.27 (1.08-1.48)
adjusted RR (95%
CI). Excess all-
cause mortality
of myocardial
injury vs T2MI.
No difference
T2MI vs
myocardial injury
for CVD
Sandoval et al
(2017)23
1640 (cTnI value
sex specific
>99th percentile)
6 (8%) all-cause
mortality at
180 days
18 (13%) all-cause
mortality at
180 days
30 (11%) all-
cause
mortality at
180 days
No difference T2MI
vs myocardial
injury
Cediel et al
(2017)24
1010 (cTnI
>0.039 μg/mL
corresponds to
99th percentile
URL with
coefficient of
variation <10%)
74 (19.7%) at
2 years
77 (39.7%) at
2 years
176 (40%) at
2 years
1.41 (1.02-1.94) HR
(95% CI)
1.54 (1.16-2.04)
HR (95% CI)
No difference T2MI
vs myocardial
injury
Gaggin et al
(2017)26
1251 (>99th
percentile URL or
lowest cTn with
<10%
imprecision)
23.3% per
100 person-
years
3.3% per
100 person-
years in non-
T2MI
2.96 (2.01-4.36) HR
(95% CI) T2MI vs
without T2MI
Sarkisian et al
(2016)11
1577 (99th
percentile URL
and coefficient if
variation of 10%
was >30 ng/L of
cTnI)
115 (31%) of
369 at
3.2 years
75 (63%) of
119 at
3.2 years
645 (59%) of
1089 at
3.2 years
1.28 (0.97-1.65) HR
(95% CI). No
difference T2MI
vs myocardial
injury
Smilowitz et al
(2016)25
475 (>99th
percentile URL of
cTn)
16 (6%) of all-
cause in-
hospital
mortality
10 (5%) of all-
cause in-
hospital
mortality
No difference T2MI
vs myocardial
injury
Shah et al
(2015)12
2165 (cTnI
≥50 ng/L)
187 (16%) of
1171 at 1 year
134 (37%) of
429 at 1 year
193 (37%) of
522 at 1 year
1.95 (1.61-2.37) RR
(95% CI)
2.36 (1.990-2.81)
RR (95% CI)
1.19 (0.99-1.42) RR
(95% CI). No
difference T2MI
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2.2 | Biomarker
All troponin samples were analyzed on the Beckman DXI800
(Beckman Instruments, Beckman Coulter, Fullerton, California). This
assay has a 99th percentile URL value of 30 ng/L with a coefficient of
variation of 10% at 40 ng/L. We used a threshold of 40 ng/L for
detection of myocardial injury during the study period.2,31
2.3 | Identification of study population and patient
selection
Patients with elevated cTnI >40 ng/L from 1 January 2009 to
31 December 2010 were identified using data extracted from CTSI.
Due to the absence of International Classification of Disease, Ninth
Revision (ICD-9) code for T2MI and myocardial injury and since
administrative coding for T2MI in ICD-10 were only available in
October 2017, ascertainment of T2MI will rely on primary chart
review. To limit patients with presumed T1MI, those with ICD-9
diagnosis of acute MI (410.xx, 411.1) have been excluded from the
initial inclusion criteria. The study will exclude patients with pre-
hospital cardiac arrest, patients who were transferred from an out-
side hospital more than 24 hours after the presentation (to limit
selection of patients requiring higher levels of care to minimize the
transfer of incomplete or inaccurate information), T1MI diagnosed
by discharging physician, traumatic brain injury, readmission, one
troponin I level, and significant missing data to sufficiently adjudi-
cate T2MI vs myocardial injury. Data of patients who met the inclu-
sion criteria will be entered into a secure, customized electronic
adjudication system for review.
TABLE 1 (Continued)
Study N
Mortality of T1MI
patients
Mortality of T2MI
patients
Mortality of
myocardial
injury patients
Mortality of T2MI
vs T1MI patients
Mortality of
myocardial injury
vs T1MI patients
Mortality of T2MI
vs myocardial
injury
vs myocardial
injury
Baron et al
(2015)13
19 763 (AMI
patients)
13.5% at 1 year 24.7% at 1 year 1.86 (1.66-2.08) HR
(95% CI)
unadjusted at
1 year. Adjusted
with age, sex,
comorbidities,
treatment and
cTnI level 1.03
(0.86-1.23)
Spatz et al
(2015)27
2082 (AMI
patients)
53 (2.2%) at
1 year
3 (2.4%) at 1 year
Sandoval et al
(2014)4
1112 (cTnI
>34 ng/L
corresponds to
99th percentile
URL and 10%
coefficient of
variation)
7.60% death at
180 days
11.4% deaths at
180 days
Saaby et al
(2013,
2014)9,15
553 (cTnI
>0.03 μg/L)
92 (25.6%) of
360 at
2.1 years
58 (48.7%) of
119 at
2.1 years
2.3 (1.7-3.3) HR
(95% CI)
univariable Cox
regression
analyses
Stein et al
(2014)14
2818 (ACS
patients)
8.6% at 1 year 23.9% at 1 year
El-Haddad
(2012)28
807 (cTnI
≥1.6 ng/mL)
28 (5.4%) of
512 at 1 year
84 (28.5%) of
295 at 1 year
Javed et al
(2009)8
216 (cTnI
>0.04 ng/mL)
15 (11%) of
143 in-hospital
mortality
9 (14%) of 64 in-
hospital
mortality
67 (15%) of
461 non-MI
group in-
hospital
mortality
Abbreviations: ACS, acute coronary syndrome; AMI, acute myocardial infarction; CAD, coronary artery disease; CI, confident interval; cTnI, cardiac
troponin I; cTnT, cardiac troponin T; CVD, cardiovascular death; Hb, hemoglobin; HR, hazard ratio; HTN, hypertension; MI, myocardial infarction; NA, not
available; NSTEMI, non-ST elevation myocardial infarction; PVD, peripheral vascular disease; RR, relative risk; T1MI, type 1 myocardial infarction; T2MI,
type 2 myocardial infarction.
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2.4 | Ascertainment of clinical data
2.4.1 | Presentation
Emergency department notes or admitting physician's notes will be
the source of information on the initial presentation of patients
(Figure 2). Further information on variables collected during the hospi-
tal course, traditional comorbidities and risk factors, baseline medica-
tions, laboratory testing variables are provided in Appendix S1.
2.4.2 | Follow-up
A follow-up at 180 days, 1 year, 5, and 7 years of all subjects included
in the registry will be conducted via a review of the electronic medical
records system. At each follow-up time-point, health status and any
interim cardiovascular (CV) events will be recorded. Vital status will be
assessed via the NDI and North Carolina State Vital Statistics includ-
ing the cause of death.
2.5 | Adjudication of T2MI and myocardial injury
A team of trained study physicians will review all records and utilize
the Fourth Universal Definition to classify patients into (a) T2MI,
(b) acute myocardial injury, and (c) chronic myocardial injury2
(Figure 3). All diagnoses will be adjudicated by two independent adju-
dicators with disagreements settled by a third adjudicator. All
reviewers will have access to all available electronic patient medical
records from the index admission described above. To fulfill the bio-
marker criteria of T2MI, an elevated cTnI of at least >40 ng/L along
with an evidence of rise and/or fall of cTnI will be required. If the bio-
marker criteria is met, clinical conditions with potential to trigger overt
ischemia along with any one of the following will be required to be
diagnosed as T2MI: (a) symptoms or signs of ischemia recorded in the
medical chart; (b) new or presumed new (if unknown baseline) signifi-
cant ST-segment/T-wave changes or new left bundle branch block;
(c) development of pathologic Q waves on electrocardiogram; and
(d) imaging evidence of new loss of viable myocardium or new
regional wall-motion abnormality.1,2 For a diagnosis of acute myocar-
dial injury, an elevated cTnI of at least >40 ng/L along with an evi-
dence of newly detected dynamic rising and/or falling pattern of cTnI
and clinical conditions without overt myocardial ischemia will be
required. For a diagnosis of chronic myocardial injury, an elevated
cTnI of at least >40 ng/L along with stable and unchanging pattern of
cTnI and clinical conditions without myocardial ischemia2 will be
required.
2.6 | Study endpoints
Causes of death will be classified in 1 of 3 categories (1) CV death
(secondary to MI, heart failure, sudden cardiac death, stroke, CV pro-
cedure, and other CV causes such as pulmonary embolism or periph-
eral artery disease), (2) non-CV death, and (3) undetermined cause of
death (Appendix S2). Name, social security numbers, and date of birth
will be used to match patients with the NDI/North Carolina State
Vital Statistics to identified deaths at follow-up. The definition of CV
death will be adapted from the 2014 American College of Car-
diology/American Heart Association key data elements and defini-
tions for CV endpoints in clinical trials.32 No formal sub-studies are
planned in this study.
2.7 | Data management
All study-related patient data will be stored on REDCap (Research
Electronic Data Capture) tools hosted by Wake Forest CTSI. REDCap
is a secure, encrypted, web application for building and managing the
online database. REDCap is a Health Insurance Portability and
F IGURE 1 Scheme of the Wake-Up
T2MI Registry design
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Accountability Act compliant. This web serves as an intuitive interface
to enter data with real-time validation (automated data type and range
checks). This platform offers easy data manipulation with audit trails
and reports for monitoring and querying of participant records.33
2.8 | Statistical analysis
Continuous variables will be reported as means or medians and com-
pared with t tests, Wilcoxon rank-sum, or analysis of variance, as appro-
priate. Categorical variables will be reported as proportions and
frequencies and will be compared with chi-square or Fisher exact tests.
Ordinal variables will be compared with a trend test. Cox proportional
hazardsmodelingwill be performed for time-to-event analyses. All analy-
sis will be performed on de-identified data. All analysis was performed
using SAS software, version 9.4 (SAS Institute, Inc., Cary, North Carolina).
3 | RESULTS
3.1 | Baseline clinical profile of T2MI or myocardial
injury
We plan to collect data from a total of 2846 patients, who met our
inclusion criteria over a period of 1 January 2009 to 31 December
2010. As of November 2018, we have collected data for a total of
2205 patients. The baseline characteristics of this initial cohort are
detailed in Table 3. The mean age was 65.6 ± 16.9 years, 52.2% were
women, and 64% were white. Over two-thirds (71%) had hyperten-
sion, 35% had hyperlipidemia, 30% had diabetes mellitus, and 18.5%
had chronic kidney disease at baseline (Table 3). At the time of hospi-
tal admission, 40% were on aspirin, 38% were on β-blockers, 30%
were on statins, 29% were on angiotensin-converting enzyme inhibi-
tors, and 9% were on angiotensin II receptor blockers (Table 3).
4 | DISCUSSION
The increasing sensitivity of troponin assays, their wide ranging use,
and heightened recognition by clinicians have contributed to an
increase in diagnoses of T2MI and myocardial injury. These clinical
entities have drawn more attention largely related to challenges in
their management and poor short- and long-term outcomes. To date,
there have been few randomized clinical trials available to determine
the effects of investigational strategies in these cohorts.34,35 As such,
observational studies defining the epidemiology of these disease enti-
ties are of great importance. In the CASABLANCA study26 (Catheter
Sampled Blood Archive in Cardiovascular Diseases) (ClinicalTrials.gov
F IGURE 2 Ascertainment of clinical
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NCT00842868), a prospective single center cohort examined 1251
patients undergoing coronary and peripheral angiographic procedures,
73.8% had at least one incident of T2MI in median of 40 months
follow-up and found 61% of T2MI had ≥50% coronary obstruction in
≥2 vessels. The role of CAD and mechanism of myocardial injury is
being studied in the ongoing, prospective Determining the Mechanism
of Myocardial Injury and Role of Coronary Disease in Type 2 Myocar-
dial Infarction (DEMAND-MI) study (ClinicalTrials.gov
NCT03338504). The perioperative period is a unique clinical scenario
where patients have high risk of T2MI and myocardial injury.
Incidence and Outcome of Perioperative Myocardial Injury After Non-
cardiac Surgery (BASAL-PMI) study (NCT02573532) is an ongoing
observational perioperative study classifying patients into T1MI,
T2MI, or myocardial injury using high-sensitivity cTn assays. Diagnos-
tic strategies to better characterize these entities are urgently needed,
as well as targeted therapies to improve outcomes in these patients.
Upon completion of data extraction, the Wake-Up T2MI Registry
will be useful in evaluating use of cardioprotective therapies and their
association with long-term outcomes in this cohort. We would define
underlying comorbid disease burden including CAD, peripheral vascu-
lar diseases, chronic obstructive pulmonary diseases, obstructive sleep
apnea, obesity, hyperlipidemia, and diabetes mellitus. In addition, we
would identify important risk predictors of subsequent clinical out-
comes, which may help to guide development of strategies to improve
outcomes in various subgroups. Furthermore, we plan to evaluate
electrocardiographic, imaging, and biomarker signatures of these dis-
ease states.
The Wake-Up T2MI Registry will generate high-quality clinical
data and its longitudinal design will enable follow-up of short- and
long-term outcomes. Results from this registry may be used to struc-
ture future risk-prediction models aimed at T2MI and myocardial
injury. Ultimately, results from our registry will provide data on how
to delineate better these entities, determine their cardiovascular prog-
nosis, and potentially develop strategies to mitigate their risk. Pres-
ently, we have collected data for 2205 of the 2846 planned subjects;
careful adjudication will continue to be undertaken to differentiate
T2MI, acute myocardial injury, and chronic myocardial injury. Once
study participants are adjudicated into gold standard diagnoses, we
might better address questions regarding how baseline characteristics
as a function of diagnosis, acute management, and prognosis differ.
4.1 | Study limitations
This retrospective cohort study is subject to certain limitations inher-
ent to its design. Our study is limited to single center in one US region,
and as such, results may not be fully generalizable. To facilitate long-
term clinical follow-up beyond 5 years, we enrolled patients in 2009
to 2010 period; this experience may thus not reflect contemporary
treatment practices. Although we rely on retrospective data, individual
chart review of all patients and non-reliance on coded or administra-
tive data fields will strengthen these data. During the period when the
index hospitalizations was identified (2009-2010), our center used
conventional troponin assays; therefore, there is a potential to miss
patients who could have been labeled as T2MI or myocardial injury
F IGURE 3 Adjudication criteria in the Wake-Up T2MI Registry
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based on high-sensitivity assays. We used a cut-off of troponin value
>40 ng/L to obtain a coefficient of variation of 10% and therefore, we
may have underestimated the number of patients with myocardial
injury. Due to exclusion of all patients coded as presumed T1MI, we
may miss patients who were initially clinically misidentified as T1MI
(who may have T2MI or myocardial injury).
4.2 | Conclusions
The Wake-Up T2MI Registry will collect a large cohort of patients
with T2MI and myocardial injury. By linking robust electronic health
record system administrative coding, detailed chart review with inde-
pendent adjudication, and national and state death records, we will
obtain comprehensive data that will allow us to characterize
differences in the presence and treatment of risk factors, as well as
short- and long-term outcomes. More granular data regarding T2MI
and myocardial injury are needed to guide treatment strategies in
these at-risk populations.
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